News

• FDA approves generic teriparatide and levetiracetam
• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs

Research

• Generic medications in the Lebanese community: understanding and public perception
• Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
• Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
• Impact of e-bidding procurement on generic omeprazole injection prices in Thailand

General

• Generic drug growth in Brazil and Venezuela
• Market penetration of generic drugs in Mexico and Brazil
• FDA releases one-year progress report for the Generic Drug Cluster
• Pharmaceutical manufacturing companies in Brazil

News

• Three more biosimilar approvals in Canada in 2023
• EMA recommends approval of first omalizumab biosimilar Omlyclo
• China approves first denosumab copy biological Maiweijian
• EMA recommends approval of first denosumab biosimilar Jubbonti and Wyost

Research

• Unveiling key clinical findings for denosumab biosimilar candidates
• Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
• Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
• Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies

General

• Addressing the persistent gap in Medicare access to Humira biosimilars
• Biosimilars of omalizumab
• Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
• Insurer perspective on increasing biosimilar uptake in Canada

• Latin American Forum
• Non‐Biological Complex Drugs
• Country Focus

• Guidelines
• Policies & Legislation
• Reports

• Conferences
• Sponsored Articles
• Sponsored Links